Skip to main content
SpringerLink
Log in

Hodgkin Lymphoma and PD-1 Blockade

  • Chapter
  • First Online:
Hodgkin Lymphoma

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

  • 1093 Accesses

Abstract

Classical Hodgkin lymphoma (cHL) is characterized by nearly universal genetic alterations at 9p24.1, resulting in increased expression of PD-1 ligands and immune evasion. Disruption of the PD-1 pathway with anti-PD-1 monoclonal antibodies (mAbs) can restore an antitumor immune response in many patients. Based on high overall response rates in cHL patients with relapsed or refractory (R/R) disease, two PD-1 mAbs, nivolumab and pembrolizumab, received accelerated approval in North America and Europe. Currently, numerous ongoing trials are combining PD-1 mAbs with rationally selected agents in the R/R setting and testing PD-1 blockade earlier in the treatment paradigm with potentially curative therapies. These trials and a rapidly improving understanding of mechanisms of immune resistance to PD-1 blockade have the potential to further improve outcomes for patients with cHL.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Küppers R (2009) The biology of Hodgkin’s lymphoma. Nat Rev Cancer 9:15–27

    Article  CAS  PubMed  Google Scholar 

  2. Green MR, Monti S, Rodig SJ et al (2010) Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116:3268–3277

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Green MR, Rodig S, Juszczynski P, Ouyang J, Sinha P, O’Donnell E, Neuberg D, Shipp MA (2012) Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res 18:1611–1618

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Yamamoto R, Nishikori M, Kitawaki T et al (2008) PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 111:3220–3224

    Article  CAS  PubMed  Google Scholar 

  5. Roemer MGM, Advani RH, Ligon AH et al (2016) PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol 34:2690–2697

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Ansell SM, Lesokhin AM, Borrello I et al (2014) PD-1 blockade with Nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 372:311–319

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Armand P, Shipp MA, Ribrag V et al (2016) Programmed Death-1 blockade with Pembrolizumab in patients with classical Hodgkin lymphoma after Brentuximab Vedotin failure. J Clin Oncol 34:3733. https://doi.org/10.1200/JCO.2016.67.3467

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Armand P, Shipp MA, Ribrag V, Michot J-M, Zinzani PL, Kuruvilla J, Zhu Y, Ricart AD, Balakumaran A, Moskowitz CH (2016) Pembrolizumab in patients with classical Hodgkin lymphoma after Brentuximab Vedotin failure: long-term efficacy from the phase 1b Keynote-013 study. Blood 128:1108

    Article  Google Scholar 

  9. Armand P, Engert A, Younes A et al (2018) Nivolumab for relapsed/refractory Classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol 36:1428–1439

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Zinzani PL (2018) Two-year follow-up of keynote-087 study: pembrolizumab monotherapy in relapsed/refractory classic Hodgkin lymphoma. Blood 132(Supplement 1):2900

    Article  Google Scholar 

  11. Chen R, Zinzani PL, Fanale MA et al (2017) Phase II study of the efficacy and safety of Pembrolizumab for relapsed/refractory Classic Hodgkin lymphoma. J Clin Oncol 35:2125–2132

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Zhu J, Feng J, Chen X, Lin T, Cao J, Liu Y, Zhao Y, Jin J, Huang H, Hu J, Luo J, Zhang L, Xue H, Zhang QYY (2018) A phase ii study of SHR-1210, an anti-PD-1 antibody, in CHINESE patients with relapsed/refractory CLASSIC HODGKIN lymphoma. HemaSphere 2:41

    Google Scholar 

  13. Shi Y, Su H, Song Y, Jiang W, Sun X, Qian W, Zhang W, Gao Y, Jin Z, Zhou J, Jin C, Zou L, Qiu L, Li W, Yang J, Hou M, Zeng S, Liu P, Zhou HLX (2018) Sintilimab (IBI308) in relapsed/refractory classical Hodgkin lymphoma: a multicenter, single-arm phase 2 trial in China (ORIENT-1 study). J Clin Oncol 36:2018

    Article  Google Scholar 

  14. Song Y, Gao Q, Zhang H et al (2018) Tislelizumab (BGB-A317) for relapsed/refractory classical Hodgkin lymphoma: preliminary efficacy and safety results from a phase 2 study. Blood 132:682–682

    Article  Google Scholar 

  15. Chen R, Gibb AL, Collins GP et al (2017) Blockade of the PD-1 checkpoint with anti-PD-L1 antibody AVELUMAB is sufficient for clinical activity in relapsed/refractory classical HODGKIN lymphoma (CHL). Hematol Oncol 35:67–67

    Article  Google Scholar 

  16. Chiou VL, Burotto M (2015) Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 33:3541–3543

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Dercle L, Ammari S, Seban R-D et al (2018) Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma. Eur J Cancer 91:136–144

    Article  CAS  PubMed  Google Scholar 

  18. Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA, Hoos A, Barrington SF, Armand P (2016) Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 128:2489–2496

    Article  CAS  PubMed  Google Scholar 

  19. Younes A, Hilden P, Coiffier B et al (2017) International working group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol off J Eur Soc Med Oncol 28:1436–1447

    Article  CAS  Google Scholar 

  20. Spina V, Bruscaggin A, Cuccaro A et al (2018) Circulating tumor DNA reveals genetics, clonal evolution and residual disease in classical Hodgkin lymphoma. In: Blood, vol 131, p 2413

    Google Scholar 

  21. Younes A, Santoro A, Shipp M et al (2016) Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 17:1283–1294

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Tumeh P, Harview C, Yearley J, Al E (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568–571

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Im SJ, Hashimoto M, Gerner MY et al (2016) Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537:417–421

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Kamphorst AO, Wieland A, Nasti T et al (2017) Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent. Science 355:1423–1427

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Diepstra A, van Imhoff GW, Karim-Kos HE et al (2007) HLA class II expression by Hodgkin reed-Sternberg cells is an independent prognostic factor in classical Hodgkin’s lymphoma. J Clin Oncol 25:3101–3108

    Article  PubMed  Google Scholar 

  26. Roemer MGM, Redd RA, Cader FZ et al (2018) Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in Classic Hodgkin lymphoma. J Clin Oncol 36:942–950

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Carey CD, Gusenleitner D, Lipschitz M et al (2017) Topological analysis reveals a PD-L1 associated microenvironmental niche for reed-Sternberg cells in Hodgkin lymphoma. In: Blood, vol 130, p 2420

    Google Scholar 

  28. Vari F, Arpon D, Keane C et al (2018) Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. Blood 131:1809–1819

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Huard B, Prigent P, Tournier M, Bruniquel D, Triebel F (1995) CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. Eur J Immunol 25:2718–2721

    Article  CAS  PubMed  Google Scholar 

  30. Huang C-T, Workman CJ, Flies D et al (2004) Role of LAG-3 in regulatory T cells. Immunity 21:503–513

    Article  CAS  PubMed  Google Scholar 

  31. Twyman-Saint Victor C, Rech AJ, Maity A et al (2015) Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520:373–377

    Article  CAS  PubMed  Google Scholar 

  32. Koyama S, Akbay EA, Li YY et al (2016) Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun 7:10501

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Hollander P, Amini R-M, Ginman B, Molin D, Enblad G, Glimelius I (2018) Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma. PLoS One 13:e0204870

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Sasse S, Reddemann K, Diepstra A, Oschlies I, Schnitter A, Borchmann S, Engert A, Borchmann P, Klapper W (2018) Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment. Haematologica haematol 2018:196279

    Google Scholar 

  35. Johnson P, Federico M, Kirkwood A et al (2016) Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med 374:2419–2429

    Article  PubMed  PubMed Central  Google Scholar 

  36. Connors JM, Jurczak W, Straus DJ et al (2018) Brentuximab Vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med 378:331–344

    Article  CAS  PubMed  Google Scholar 

  37. Ramchandren R, Fanale MA, Rueda A et al (2017) Nivolumab for newly diagnosed advanced-stage classical Hodgkin lymphoma (cHL): results from the phase 2 Checkmate 205 study. Blood 2017:130

    Google Scholar 

  38. Schmitz N, Pfistner B, Sextro M et al (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet (London, England) 359:2065–2071

    Article  CAS  Google Scholar 

  39. Moskowitz CH, Nademanee A, Masszi T et al (2015) Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England) 385:1853–1862

    Article  CAS  Google Scholar 

  40. Herrera AF, Moskowitz AJ, Bartlett NL et al (2018) Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 131:1183–1194

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Herrera A, Moskowitz A, Bartlett N, Vose J, Ramchandren R, Feldman T, LaCasce A, Ansell S, Moskowitz C, Fenton K, Sacchi M, Galderisi AR (2018) Brentuximab Vedotin in combination with Nivolumab in patients with relapsed or refractory Hodgkin lymphoma: follow-up results from the phase 1/2 study. HemaSphere ISHL 2018

    Google Scholar 

  42. Porrata LF, Litzow MR, Markovic SN (2001) Immune reconstitution after autologous hematopoietic stem cell transplantation. Mayo Clin Proc 76:407–412

    Article  CAS  PubMed  Google Scholar 

  43. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G (2013) Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 39:74–88

    Article  CAS  PubMed  Google Scholar 

  44. Armand P, Chen Y-B, Redd R, Joyce R, Bsat J, Merryman R, Coleman K, Dahi P, Nieto Y, LaCasce A, Fisher D, Ng S, Odejide O, Freedman A, Kim A, Crombie J, Jacobson C, Jacobsen E, Wong J, Patel S, Ritz J, Rodig S, Shipp MHA (2019) PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood 134(1):22–29

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23–34

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Ansell S, Gutierrez ME, Shipp MA et al (2016) A phase 1 study of Nivolumab in combination with Ipilimumab for relapsed or refractory hematologic malignancies (CheckMate 039). Blood 128:183

    Article  Google Scholar 

  47. Rothe A, Sasse S, Topp MS et al (2015) A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood 125:4024–4031

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Ansell SM, Chen RW, Forero-Torres A, Armand P, Lossos IS, Reeder CB, Strassz A, Kerber A, Bartlett NL (2017) A phase 1 study investigating the combination of AFM13 and the monoclonal anti-PD-1 antibody Pembrolizumab in patients with relapsed/refractory Hodgkin lymphoma after Brentuximab Vedotin failure: data from the dose escalation part of the study. Blood 130(Supplement 1):1522

    Google Scholar 

  49. Hao Y, Chapuy B, Monti S, Sun HH, Rodig SJ, Shipp MA (2014) Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo. Clin Cancer Res 20:2674–2683

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Van Den Neste E, André M, Gastinne T et al (2018) A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma. Haematologica 103:840–848

    Article  CAS  Google Scholar 

  51. Younes A, Romaguera J, Fanale M et al (2012) Phase I study of a novel Oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol 30:4161–4167

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Locatelli SL, Consonni FM, Careddu G, Serio S, Viswanadha S, Vakkalanka S, Castagna L, Santoro A, Carlo-Stella C (2016) Treatment of Hodgkin lymphoma xenografts with the novel PI3K δ/γ inhibitor RP6530 suppresses M2 macrophage polarization and results in potent antitumor and antiangiogenic effects. Blood 128:45

    Article  Google Scholar 

  53. Locatelli SL, Careddu G, Serio S et al (2019) Targeting cancer cells and tumor microenvironment in preclinical and clinical models of Hodgkin lymphoma using the dual PI3Kδ/γ inhibitor RP6530. Clin Cancer Res 25(3):1098–1112

    Article  CAS  PubMed  Google Scholar 

  54. Sagiv-Barfi I, Kohrt HEK, Czerwinski DK, Ng PP, Chang BY, Levy R (2015) Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci U S A 112:E966–E972

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Chiappinelli KB, Strissel PL, Desrichard A et al (2015) Inhibiting DNA methylation causes an interferon response in Cancer via dsRNA including endogenous retroviruses. Cell 162:974–986

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Falchi L, Sawas A, Deng C, Amengual JE, Colbourn DS, Lichtenstein EA, Khan KA, Schwartz LH, O’Connor OA (2016) High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy. J Hematol Oncol 9:132

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Formenti SC, Demaria S (2009) Systemic effects of local radiotherapy. Lancet Oncol 10:718–726

    Article  PubMed  PubMed Central  Google Scholar 

  58. Michot J-M, Mazeron R, Dercle L et al (2016) Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody. Eur J Cancer 66:91–94

    Article  PubMed  Google Scholar 

  59. Wight JC, Hawkes EA, Berlangieri SU, Khor R, Grigg AP (2018) An abscopal effect may augment PD-1 inhibition in refractory classical Hodgkin lymphoma. Leuk Lymphoma 59(11):2749–2751

    Article  PubMed  Google Scholar 

  60. Rossi C, Gilhodes J, Maerevoet M et al (2017) Efficacy of chemotherapy or chemo-anti-PD-1 combination after unsatisfactory response of anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: a retrospective series from Lysa centers. Blood 130:652

    Google Scholar 

  61. Carreau NA, Pail O, Armand P, Merryman R, Advani RH, Spinner MA, Herrera AF, Chen R, Tomassetti S, Ramchandren R, Hamid M, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair S, Barta SK, Liu Y, Nathan S, Karmali R, Burkart M, Torka P, Dav DC (2018) Checkpoint blockade therapy may sensitize Hodgkin lymphoma to subsequent therapy. Blood ASH abstra, vol 132, p 1626

    Google Scholar 

  62. Merryman RW, Armand P (2017) Immune checkpoint blockade and hematopoietic stem cell transplant. Curr Hematol Malig Rep 12:44–50

    Article  PubMed  Google Scholar 

  63. Herbaux C, Merryman R, Devine S, Armand P, Houot R, Morschhauser F, Haverkos B (2018) Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. Blood 132:9–16

    Article  CAS  PubMed  Google Scholar 

  64. Merryman RW, Kim HT, Zinzani PL et al (2017) Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood 129:1380–1388

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Castagna L, Magagnoli M, Mazza R, Morello L, Ricci F, Bramanti S, Sarina B, Mariotti J, De Philippis C, Sica S, Rodari M, Sollini M, Kirienko M, Chiti A, Santoro A (2018) Allogeneic stem cell transplantation (Allo-SCT) for relapsed/refractory classical Hodgkin lymphoma (cHL) patients treated with Nivolumab is associated with an unprecedented low relapse rate. HemaSphere ISHL 2018

    Google Scholar 

  66. Schoch LK, Cooke KR, Wagner-Johnston ND et al (2018) Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv 2:2226–2229

    Article  PubMed  PubMed Central  Google Scholar 

  67. Herbaux C, Gauthier J, Brice P et al (2017) Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood 129:2471–2478

    Article  CAS  PubMed  Google Scholar 

  68. Haverkos BM, Abbott D, Hamadani M et al (2017) PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood 130:221–228

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Davids MS, Kim HT, Costello C et al (2017) Optimizing checkpoint blockade as a treatment for relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Blood 2017:130

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

    Reid Merryman & Philippe Armand

  2. Mayo Clinic, Rochester, MN, USA

    Stephen Ansell

Authors
  1. Reid Merryman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Philippe Armand
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephen Ansell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen Ansell .

Editor information

Editors and Affiliations

  1. Department of Internal Medicine, University Hospital Cologne, Köln, Nordrhein-Westfalen, Germany

    Andreas Engert

  2. Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Anas Younes

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Merryman, R., Armand, P., Ansell, S. (2020). Hodgkin Lymphoma and PD-1 Blockade. In: Engert, A., Younes, A. (eds) Hodgkin Lymphoma. Hematologic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-030-32482-7_23

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-32482-7_23

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-32481-0

  • Online ISBN: 978-3-030-32482-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation